Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D1.481 - Prevalence of Immunoglobulin Deficiency in Patients with Chronic Rhinosinusitis Followed in a Tertiary Referral Center
D1.487 - Evaluation of Large Language Models in Otolaryngology: Accuracy on Structured Question Banks and S.C.O.R.E.-Based Interpretation of Guidelines and Consensus Statements
D1.485 - Characterization of CRSwNP and associated Type 2 or Respiratory comorbidities in the biological era in Spain - The POLARIS study
D1.486 - Epidemiological Investigation of Pollen induced Allergic Diseases in China
D1.489 - The establishment and characteristics of type 2 inflammation in nasal organoids
D1.490 - Dupilumab in the treatment of Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Cystic Fibrosis patients
D1.492 - Efficacy and safety of a combined nasal spray with a fixed dose of mometasone and olopatadine for the treatment of allergic rhinitis in pets under save ongoing exposure to epidermal allergens
D1.493 - Circulating Exosomal miR-200 Family Downregulation in Allergic Rhinitis
- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells
- D1.529 - Evaluating the Disease-Modifying Potential of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis: An Update on the Pivotal HARBOR Study
- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib
- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series
- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis
D2.19 - Can Drug Provocation Be Avoided in Low-Risk Quinolone Reactions?
D2.25 - Epicutaneous responses to Bradykinin Receptor 1 and 2 agonists, Histamine, and mast cell agonists in Angiotensin Converting Enzyme Inhibitor angioedema
D2.17 - Diagnostic profitability of penicilloyl-polylysine and minor determinant mixture in urgent/preferred beta-lactam allergy studies in hospitalized patients from january 2023 to december 2025
D2.18 - Evaluating the Penicillin Allergy Diagnosis Process with Real-Life Data
D2.20 - Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing
D2.21 - The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity
D2.26 - Applying a phenotype-driven diagnostic algorithm to suspected hypersensitivity reactions to biologicals: a real-world experience
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download